The Beauty Health Company (SKIN) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SKIN Revenue Growth
Revenue Breakdown (FY 2025)
SKIN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SKIN Revenue Analysis (2019–2025)
As of May 8, 2026, The Beauty Health Company (SKIN) generated trailing twelve-month (TTM) revenue of $296.1 million, reflecting moderate decline in growth of -6.7% year-over-year. The most recent quarter (Q1 2026) recorded $64.9 million in revenue, down 21.2% sequentially.
Looking at the longer-term picture, SKIN's 5-year compound annual growth rate (CAGR) stands at +20.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $398.0 million in 2023.
Revenue diversification analysis shows SKIN's business is primarily driven by Consumables (71%), and Delivery Systems (29%). With over half of revenue concentrated in Consumables, the company maintains significant focus in this area while developing other growth vectors.
When compared to Consumer Defensive sector peers including ELF (+16.7% YoY), IPAR (+1.9% YoY), and COTY (-3.6% YoY), SKIN has underperformed the peer group in terms of revenue growth. Compare SKIN vs ELF →
SKIN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SKINCurrent | $296M | -6.7% | +20.4% | -6.9% | |
 ELF | $1.3B | +16.7% | +35.9% | 12.0% | |
 IPAR | $1.5B | +1.9% | +22.5% | 18.2% | |
 COTY | $5.9B | -3.6% | +4.5% | 4.1% | |
 NUS | $1.5B | -14.3% | -10.5% | 6.1% | |
 USNA | $925M | +8.3% | -4.0% | 5.5% |
SKIN Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $300.8M | -10.0% | $196.4M | 65.3% | $-20,800,000 | -6.9% |
| 2024 | $334.3M | -16.0% | $182.3M | 54.5% | $-67,774,000 | -20.3% |
| 2023 | $398.0M | +8.8% | $155.1M | 39.0% | $-130,917,000 | -32.9% |
| 2022 | $365.9M | +40.7% | $248.8M | 68.0% | $-25,841,000 | -7.1% |
| 2021 | $260.1M | +118.4% | $178.5M | 68.6% | $-39,928,000 | -15.4% |
| 2020 | $119.1M | -28.5% | $67.2M | 56.4% | $-17,182,000 | -14.4% |
| 2019 | $166.6M | - | $106.5M | 63.9% | $13.5M | 8.1% |
See SKIN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKIN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKIN vs WMT
Side-by-side business, growth, and profitability comparison vs Walmart Inc..
Start ComparisonSKIN — Frequently Asked Questions
Quick answers to the most common questions about buying SKIN stock.
Is SKIN's revenue growth accelerating or slowing?
SKIN revenue declined -6.7% year-over-year, contrasting with the 5-year CAGR of +20.4%. TTM revenue fell to $296M. This reverses the prior growth trend.
What is SKIN's long-term revenue growth rate?
The Beauty Health Company's 5-year revenue CAGR of +20.4% reflects the variable expansion pattern. Current YoY growth of -6.7% is below this long-term average.
How is SKIN's revenue distributed by segment?
SKIN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.